CORT logo

CORT

Profile

Full Name

Corcept Therapeutics Incorporated

Ticker Symbol

CORT

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 14, 2004

Indexes

Not included

Website

http://www.corcept.com

Employees

500

Key Details

Price

$71.71(-0.11%)

Market cap

$7.57B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$675.04M(+39.94% YoY)

Annual EPS

$1.23(+30.85% YoY)

PE ratio

57.83

Next earnings date

May 1, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$71.71
CORT price is $71.71

30-Day Relative Volume

0.62
CORT 30-day relative volume is 0.62

Price Performance

Price Most recent change

-0.11%
CORT price was down -0.11% on Apr 25, 2025

Price YTD change

+42.31%
CORT price is up +42.31% since January 1st

Price 1-year change

+222.87%
CORT price is up +222.87% year-on-year

Price 3-year change

+215.07%
CORT price is up +215.07% over the past 3 years

Price Range

Price All-time high

$117.33
CORT price is currently -38.88% below its historical high of $117.33

Price 3-year low

$17.19
CORT price is currently +317.16% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$7.57B
CORT market capitalization is $7.57 billion

Market cap 3-year change

+212.86%
CORT market capitalization is up +212.86% over the past 3 years

Market cap All-time high

$12.05B
CORT market capitalization is currently -37.22% below its historical high of $12.05 billion

Market cap sector rank

91.3%
CORT market capitalization is higher than 91.3% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.6%
CORT shares outstanding is up +1.6% year-on-year

Shares Outstanding 3-Year Change

-0.7%
CORT shares outstanding is down -0.7% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.14
CORT beta is 1.14

200-day SMA

$51.92
CORT price is currently +38.12% above its 200-day simple moving average

50-day SMA

$65.26
CORT price is currently +9.88% above its 50-day simple moving average

RSI

53.82
CORT 14-day relative strength index is 53.82

Volume

0.62
CORT 30-day relative volume is 0.62

ATR

$5.36
CORT average true range is $5.36

10-day Historical Volatility

64.44%
CORT 10-day historical volatility is 64.44%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$675.04M
CORT annual revenue is $675.04 million

Revenue Analysts estimate

$905.38M
CORT annual revenue is currently -25.44% lower than the consensus analysts' forecast

Revenue 1-year change

+39.94%
CORT annual revenue is up +39.94% year-on-year

Revenue Sector rank

76.56%
CORT annual revenue is higher than 76.56% of companies in Healthcare sector

EPS

EPS

$1.23
CORT annual earnings per share is $1.23

EPS Analysts estimate

$1.70
CORT annual earnings per share is currently -27.43% lower than the consensus analysts' forecast

EPS 1-year change

+30.85%
CORT annual earnings per share is up +30.85% year-on-year

EPS Sector rank

90.07%
CORT annual earnings per share is higher than 90.07% of companies in Healthcare sector

Profit

Gross profit

$664.16M
CORT annual gross profit is $664.16 million

Gross margin

98.39%
CORT annual gross profit margin is 98.39%

Operating profit

$136.95M
CORT annual operating income is $136.95 million

Operating margin

20.29%
CORT annual operating profit margin is 20.29%

Net income

$141.21M
CORT annual net profit is $141.21 million

Net margin

20.92%
CORT annual net profit margin is 20.92%

Expenses

Total expenses

$538.09M
CORT annual total expenses is $538.09 million

Operating expenses

$527.21M
CORT annual total operating expenses is $527.21 million

Cost of goods sold

$10.88M
CORT annual cost of goods sold is $10.88 million

Selling, general & administrative expenses

$280.32M
CORT annual SGA is $280.32 million

Depreciation and amortization

$1.34M
CORT annual depreciation & amortization is $1.34 million

Interest expense

-
CORT annual interest expense value is unknown

Income tax

$20.28M
CORT annual income tax is $20.28 million

EBIT & EBITDA

EBIT

$136.95M
CORT annual earnings before interest & taxes is $136.95 million

EBITDA

$138.29M
CORT annual EBITDA is $138.29 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$840.55M
CORT annual total assets is $840.55 million

Non current assets

$368.95M
CORT annual long term assets is $368.95 million

Current assets

$471.60M
CORT annual total current assets is $471.60 million

Cash and cash equivalents

$127.67M
CORT annual cash & cash equivalents is $127.67 million

Accounts receivable

$53.98M
CORT annual accounts receivable is $53.98 million

Inventory

$12.41M
CORT annual inventory is $12.41 million

Liabilities

Total liabilities

$160.96M
CORT annual total liabilities is $160.96 million

Long term liabilities

$20.19M
CORT annual total long term liabilities is $20.19 million

Current liabilities

$140.77M
CORT annual total current liabilities is $140.77 million

Accounts payable

$15.38M
CORT annual accounts payable is $15.38 million

Debt

Total debt

$6.94M
CORT annual total debt is $6.94 million

Total debt 1-year change

+4493.38%
CORT annual total debt is up +4493.38% year-on-year

Long term debt

$6.11M
CORT annual long term debt is $6.11 million

Short term debt

$829.00K
CORT annual short term debt is $829.00 thousand

Equity & Capital

Shareholders equity

$679.59M
CORT annual stockholders equity is $679.59 million

Book value

$679.59M
CORT annual book value is $679.59 million

Retained earnings

$543.74M
CORT annual retained earnings is $543.74 million

Working capital

$330.83M
CORT annual working capital is $330.83 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$198.07M
CORT annual cash flow from operations is $198.07 million

Cash from operations 1-year change

+55.91%
CORT annual cash flow from operations is up +55.91% year-on-year

Cash from investing

-$177.60M
CORT annual cash flow from investing activities is -$177.60 million

Cash from investing 1-year change

-295.37%
CORT annual cash flow from investing activities is down -295.37% year-on-year

Cash from financing

-$28.35M
CORT annual cash flow from financing activities is -$28.35 million

Cash from financing 1-year change

+80.94%
CORT annual cash flow from financing activities is up +80.94% year-on-year

CAPEX

CAPEX

$2.17M
CORT annual capital expenditures is $2.17 million

CAPEX 1-year change

+1462.59%
CORT annual capital expenditures is up +1462.59% year-on-year

Free Cash Flow

Free cash flow

$195.90M
CORT annual free cash flow is $195.90 million

Free cash flow 1-year change

+54.37%
CORT annual free cash flow is up +54.37% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

98.39%
CORT annual gross profit margin is 98.39%

Operating margin

20.29%
CORT annual operating profit margin is 20.29%

Net margin

20.92%
CORT annual net profit margin is 20.92%

ROA & ROE

ROA

19.32%
CORT annual return on assets is 19.32%

ROE

23.81%
CORT annual return on equity is 23.81%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

57.83
CORT price to earnings ratio is 57.83

PE ratio Sector rank

83.33%
CORT price to earnings ratio is higher than 83.33% of companies in Healthcare sector

PB Ratio

PB ratio

11.13
CORT price to book ratio is 11.13

PB ratio Sector rank

92.94%
CORT price to book ratio is higher than 92.94% of companies in Healthcare sector

PS Ratio

PS ratio

11.21
CORT price to sales ratio is 11.21

PS ratio Sector rank

79.09%
CORT price to sales ratio is higher than 79.09% of companies in Healthcare sector

Enterprise value

Enterprise value

$7.44B
CORT enterprise value is $7.44 billion

Enterprise value Sector rank

90.33%
CORT enterprise value is higher than 90.33% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

53.84
CORT EV/EBITDA is 53.84

EV/EBITDA Sector rank

97.36%
CORT EV/EBITDA is higher than 97.36% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

3.35
CORT annual current ratio is 3.35

Quick ratio

3.26
CORT annual quick ratio is 3.26

Leverage

Debt to equity

0.00
CORT annual debt to equity ratio is 0.00

Interest coverage ratio

-
CORT annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

5
CORT piotroski f-score is 5

Altman Z-Score

30.92
CORT altman z-score is 30.92

Analyst ratings

Recent major analysts updates

Apr 3, 25 Piper Sandler
Neutral
Apr 1, 25 Canaccord Genuity
Buy
Mar 31, 25 Truist Securities
Buy
Mar 31, 25 HC Wainwright & Co.
Buy
Feb 27, 25 Piper Sandler
Overweight
Feb 27, 25 HC Wainwright & Co.
Buy
Feb 11, 25 HC Wainwright & Co.
Buy
Feb 7, 25 HC Wainwright & Co.
Buy
Jan 30, 25 Canaccord Genuity
Buy
Oct 31, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

HALO logo
Halozyme Therapeutics (HALO)
HQY logo
HealthEquity (HQY)
ROIV logo
Roivant Sciences (ROIV)
ENSG logo
Ensign (ENSG)
MDGL logo
Madrigal Pharmaceuticals (MDGL)
RVMD logo
Revolution Medicines (RVMD)
TECH logo
Bio-Techne (TECH)
HSIC logo
Henry Schein (HSIC)
RGEN logo
Repligen (RGEN)
  • What is the ticker symbol for Corcept Therapeutics Incorporated?
  • Does Corcept Therapeutics Incorporated pay dividends?
  • What sector is Corcept Therapeutics Incorporated in?
  • What industry is Corcept Therapeutics Incorporated in?
  • What country is Corcept Therapeutics Incorporated based in?
  • When did Corcept Therapeutics Incorporated go public?
  • Is Corcept Therapeutics Incorporated in the S&P 500?
  • Is Corcept Therapeutics Incorporated in the NASDAQ 100?
  • Is Corcept Therapeutics Incorporated in the Dow Jones?
  • When was Corcept Therapeutics Incorporated's last earnings report?
  • When does Corcept Therapeutics Incorporated report earnings?
  • Should I buy Corcept Therapeutics Incorporated stock now?

What is the ticker symbol for Corcept Therapeutics Incorporated?

The ticker symbol for Corcept Therapeutics Incorporated is NASDAQ:CORT

Does Corcept Therapeutics Incorporated pay dividends?

No, Corcept Therapeutics Incorporated does not pay dividends

What sector is Corcept Therapeutics Incorporated in?

Corcept Therapeutics Incorporated is in the Healthcare sector

What industry is Corcept Therapeutics Incorporated in?

Corcept Therapeutics Incorporated is in the Biotechnology industry

What country is Corcept Therapeutics Incorporated based in?

Corcept Therapeutics Incorporated is headquartered in United States

When did Corcept Therapeutics Incorporated go public?

Corcept Therapeutics Incorporated's initial public offering (IPO) was on April 14, 2004

Is Corcept Therapeutics Incorporated in the S&P 500?

No, Corcept Therapeutics Incorporated is not included in the S&P 500 index

Is Corcept Therapeutics Incorporated in the NASDAQ 100?

No, Corcept Therapeutics Incorporated is not included in the NASDAQ 100 index

Is Corcept Therapeutics Incorporated in the Dow Jones?

No, Corcept Therapeutics Incorporated is not included in the Dow Jones index

When was Corcept Therapeutics Incorporated's last earnings report?

Corcept Therapeutics Incorporated's most recent earnings report was on Feb 26, 2025

When does Corcept Therapeutics Incorporated report earnings?

The next expected earnings date for Corcept Therapeutics Incorporated is May 1, 2025

Should I buy Corcept Therapeutics Incorporated stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page